Suppression of mucin 2 promotes interleukin-6 secretion and tumor growth in an orthotopic immune-competent colon cancer animal model

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2335-2342

  Shan, Yan Shen ^a   Hsu, Hui Ping ^a   Lai, Ming Derg ^b   Yen, Meng Chi ^b,c   Fang, Jung Hua ^b   Weng, Tzu Yang ^b   Chen, Yi Ling ^d  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Colon cancer; Interleukin 6; Mucin 2; Small interfering RNA; Therapeutic effects

Indexed keywords

INTERLEUKIN 6; SMALL INTERFERING RNA; MUC2 PROTEIN, MOUSE; MUCIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE REPRESSION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; MUC2 GENE; NONHUMAN; RNA INTERFERENCE; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLON TUMOR; DISEASE MODEL; GENETICS; IMMUNOCOMPETENCE; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SECRETION (PROCESS); TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; IMMUNOCOMPETENCE; INTERLEUKIN-6; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MUCIN-2; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; TUMOR BURDEN;

EID: 84914679965     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3544     Document Type: Article

References (36)

1. Hanski C, Hofmeier M, Schmitt-Gräff A, et al: Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 182: 385-391, 1997.
2. Velcich A, Yang W, Heyer J, et al: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726-1729, 2002.
3. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
4. Piancatelli D, Romano P, Sebastiani P, Adorno D and Casciani CU: Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother 22: 25-32, 1999.
5. Lieubeau B, Heymann MF, Henry F, Barbieux I, Meflah K and Grégoire M: Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int J Cancer 81: 629-636, 1999.
6. Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165, 2001.
7. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT and Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187, 1999.
8. Esfandi F, Mohammadzadeh Ghobadloo S and Basati G: Interleukin-6 level in patients with colorectal cancer. Cancer Lett 244: 76-78, 2006.
9. Galizia G, Orditura M, Romano C, et al: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102: 169-178, 2002.
10. Ueda T, Shimada E and Urakawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429, 1994.
11. Kinoshita T, Ito H and Miki C: Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85: 2526-2531, 1999.
12. Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222-226, 2003.
13. Li YY, Hsieh LL, Tang RP, Liao SK and Yeh KY: Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line. Cell Immunol 256: 19-26, 2009.
14. Atsumi T, Singh R, Sabharwal L, et al: Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74: 8-14, 2014.
15. Lu TJ, Lai WY, Huang CY, et al: Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein-tyrosine phosphatase-PEST. J Biol Chem 281: 38405-38417, 2006.
16. Shan YS, Fang JH, Lai MD, et al: Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules. Mol Carcinog 50: 739-750, 2011.
17. Ancrile B, Lim KH and Counter CM: Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719, 2007.
18. Fridlender ZG, Sun J, Kim S, et al: Polarization of tumor-associated neutrophil phenotype by TgF-beta: 'N1' versus 'N2' TAN. Cancer Cell 16: 183-194, 2009.
19. Ajioka Y, Allison LJ and Jass JR: Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 49: 560-564, 1996.
20. Yonezawa S, Sueyoshi K, Nomoto M, et al: MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum Pathol 28: 344-352, 1997.
21. Li A, Goto M, Horinouchi M, et al: Expression of MUC1 and MUC2 mucins and relationship with cell proliferative activity in human colorectal neoplasia. Pathol Int 51: 853-860, 2001.
22. Bresalier RS, Niv Y, Byrd JC, et al: Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 87: 1037-1045, 1991.
23. Blank M, Klussmann E, Krüger-Krasagakes S, et al: Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer 59: 301-306, 1994.
24. Ohlsson L, Israelsson A, Oberg A, et al: Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer 130: 1833-1843, 2012.
25. Kang H, Min BS, Lee KY, et al: Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol 18: 711-719, 2011.
26. Elzagheid A, Emaetig F, Buhmeida A, et al: Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma. Tumour Biol 34: 621-628, 2013.
27. Van der Sluis M, De Koning BA, De Bruijn AC, et al: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-129, 2006.
28. Eichbaum C, Meyer AS, Wang N, et al: Breast cancer cell-derived cytokines, macrophages and cell adhesion: implications for metastasis. Anticancer Res 31: 3219-3227, 2011.
29. Luboshits G, Shina S, Kaplan O, et al: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681-4687, 1999.
30. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y and Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7: 285-289, 2001.
31. Zhang GJ and Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427-1432, 1999.
32. Salgado R, Junius S, Benoy I, et al: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646, 2003.
33. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
34. Jones SA, Scheller J and Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121: 3375-3383, 2011.
35. Yen MC, Lin CC, Chen YL, et al: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15: 641-649, 2009.
36. Lin CC, Chou CW, Shiau AL, et al: Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10: 290-301, 2004.